Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: Use of a conformation-based hypothesis to facilitate compound design |
| |
Authors: | Daniel P Walker Graciela B Arhancet Hwang-Fun Lu Steven E Heasley Sue Metz Natasha M Kablaoui Francisco M Franco Cathleen E Hanau Jeffrey A Scholten John R Springer Yvette M Fobian Jeffrey S Carter Li Xing Shengtian Yang Alexander F Shaffer Gina M Jerome Michael T Baratta William M Moore Michael L Vazquez |
| |
Institution: | Pfizer Worldwide Medicinal Chemistry, Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA |
| |
Abstract: | Microsomal prostaglandin E2 synthase-1 (mPGES-1) is a novel therapeutic target for the treatment of inflammation and pain. In the preceding letter, we detailed the discovery of clinical candidate PF-04693627, a potent mPGES-1 inhibitor possessing a novel benzoxazole structure. While PF-04693627 was undergoing further preclinical profiling, we sought to identify a back-up mPGES-1 inhibitor that differentiated itself from PF-04693627. The design, synthesis, mPGES-1 activity and in vivo PK of a novel set of substituted benzoxazoles are described herein. Also described is a conformation-based hypothesis for mPGES-1 activity based on the preferred conformation of the cyclohexane ring within this class of inhibitors. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|